Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes: Two-Year Results From the Randomized, Placebo-Controlled Protégé Trial

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2013-11, Vol.62 (11), p.3901-3908
Hauptverfasser:	HAGOPIAN, William, FERRY, Robert J, LUDVIGSSON, Johnny, SHERRY, Nicole, CARLIN, David, BONVINI, Ezio, JOHNSON, Syd, STEIN, Kathryn E, KOENIG, Scott, DAIFOTIS, Anastasia G, HEROLD, Kevan C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - immunology Antibodies, Monoclonal, Humanized - pharmacokinetics Area Under Curve Biological and medical sciences C-Peptide - metabolism C-reactive protein Child Complications and side effects Diabetes Diabetes Mellitus, Type 1 - physiopathology Diabetes Mellitus, Type 1 - therapy Diabetes. Impaired glucose tolerance Dosage and administration Double-Blind Method Drug Administration Schedule Drug therapy Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Genetic aspects Glycated Hemoglobin A - metabolism Humans Hypoglycemic Agents - therapeutic use Immunotherapy Insulin Insulin - administration & dosage Insulin - therapeutic use Medical diagnosis Medical sciences Monoclonal antibodies Original Research Peptides Physiological aspects Placebos Type 1 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!